Results 101 to 110 of about 24,360 (218)

Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary

open access: yesPathology and Oncology Research
Castleman disease is a rare and atypical lymphoproliferative disorder characterized by diverse clinical manifestations. It has both unicentric and multicentric forms, the latter with further subdivisions, i.e., human herpesvirus 8-associated and ...
Boglárka Brúgós   +6 more
doaj   +1 more source

Human Herpesvirus 8 Causes a Wide Spectrum of Disease in Liver Transplant Recipients and May be Donor Derived: Case Series and Systematic Review of an Emerging Challenge

open access: yesTransplant Infectious Disease, Volume 28, Issue 5, September/October 2026.
Among 135 cases of post‐liver transplant HHV8 disease (4 from NSW), presentations varied, and mortality was high (44%). Donor screening was rare, and donor‐derived infection was suspected in 33%. Survival improved with mTORi, reduced immunosuppression, chemotherapy, and, for non‐KS disease, donor screening. ABSTRACT Background Human herpesvirus 8 (HHV8)
Karen M. J. Waller   +12 more
wiley   +1 more source

JW Castleman

open access: yes, 1977
J.W.

core  

Intrapericardial pneumonectomy for unicentric hilar castleman disease.

open access: yes, 2021
Introduction: The intrapulmonary involvement of Castleman disease is extremely rare with very few cases reported in the literature. Case report: We present a case of a 16-year-old male who underwent pulmonary resection for Castleman disease.
YEGEN, Gülçin   +4 more
core   +1 more source

Refractory Uveitis in Patient with Castleman Disease Successfully Treated with Tocilizumab

open access: yesCase Reports in Ophthalmological Medicine, 2012
Although multicentric Castleman disease is a rare but life-threatening disease, eye complications are extremely uncommon. We present a case of refractory uveitis accompanied with Castleman disease successfully treated with tocilizumab.
Toshiyuki Oshitari   +6 more
doaj   +1 more source

Quantitative analysis of a rare disease network’s international contact database and E-repository provides insights into biobanking in the electronic consent era

open access: yesOrphanet Journal of Rare Diseases, 2019
Background Castleman disease (CD) describes a group of rare and poorly understood lymphoproliferative disorders that include unicentric CD (UCD), Human Herpes Virus-8 (HHV8)-associated multicentric CD (HHV8 + MCD), and HHV8-negative/idiopathic MCD (iMCD).
Alexander Suarez   +2 more
doaj   +1 more source

Recurrent PDGFRB mutations in unicentric Castleman disease

open access: yesLeukemia, 2019
Castleman disease (CD) is a rare heterogeneous group of lymphoproliferative disorders that share common lymph node histopathological features [1, 2]. It can be classified into unicentric CD (UCD), HHV-8-positive multicentric CD (MCD) and HHV-8-negative ...
Zhao-Ming Li   +26 more
semanticscholar   +1 more source

Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan

open access: yesJournal of Clinical and Experimental Hematopathology, 2019
Castleman disease is a polyclonal lymphoproliferative disease which is clinically classified into unicentric (UCD) and multicentric (MCD). TAFRO syndrome is a relatively new concept that partly overlaps with MCD.
Y. Masaki   +10 more
semanticscholar   +1 more source

POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin lesions) syndrome: a South America's report POEMS (polineuropatia, organomegalia, endocrinopatia, proteína M, alterações de pele): relato sul-americano

open access: yesArquivos de Neuro-Psiquiatria, 2007
The POEMS syndrome, also known as Crow-Fukase syndrome, is an unusual systemic disorder described mainly in Asian individuals. It is characterized by the presence of (P)polyneuropathy, (O)organomegaly, (E)endocrinopathy, (M) M-protein, and (S) skin ...
Ana Claudia Celestino Leite   +3 more
doaj   +1 more source

P. F. Castleman [PDF]

open access: yes, 1896
R-P of P. Castleman. 17 Mar. SR 498, 54-1, v2, 2p. [3363] or HR 1558, 54-1, v6, 2p.

core  

Home - About - Disclaimer - Privacy